- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Monocl Launches Monocl Engage for Global Strategic Engagement Planning
AI-powered platform can transform medical expert and opinion leader engagement planning for medical affairs teams.
Monocl today announced the launch of Monocl Engage, a novel cloud-based global engagement planning solution built on an actionable data set for medical and scientific experts. Monocl Engage enables medical affairs leaders, as well as field medical teams, to develop strategic engagement plans on a global level that align with local activities for a comprehensive approach to developing lasting relationships with key opinion leaders and medical experts.
The product is empowered by AI-generated insights curated from millions of global data sources in real time through the Monocl platform. Monocl Engage also integrates easily with other solutions, such as leading CRM systems and internal platforms to reduce unnecessary friction. With Monocl Engage, medical affairs leaders and field medical teams have a solution which provides global engagement plan visibility and performance tracking in a single solution built specifically for this purpose.
For more information, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
